Cumberland Pharmaceuticals, Inc. (CPIX)
6.66
+0.86
(+14.83%)
USD |
NASDAQ |
Nov 18, 16:00
6.55
-0.11
(-1.65%)
After-Hours: 20:00
Cumberland Pharmaceuticals Enterprise Value : 10.64M for Nov. 17, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 17, 2026 | 10.64M |
| November 16, 2026 | 1.796M |
| November 13, 2026 | 11.84M |
| November 12, 2026 | 23.09M |
| November 11, 2026 | 15.44M |
| November 10, 2026 | 3.146M |
| November 09, 2026 | 4.195M |
| November 06, 2026 | 1.946M |
| November 05, 2026 | -1.202M |
| November 04, 2026 | -9.748M |
| November 03, 2026 | -11.70M |
| November 02, 2026 | -13.05M |
| October 30, 2026 | -6.000M |
| October 29, 2026 | -11.10M |
| October 28, 2026 | -3.301M |
| October 27, 2026 | -2.102M |
| October 26, 2026 | -11.10M |
| October 23, 2026 | 50.97M |
| October 22, 2026 | 50.82M |
| October 21, 2026 | 46.18M |
| October 20, 2026 | 43.03M |
| October 19, 2026 | 24.14M |
| October 16, 2026 | 31.33M |
| October 15, 2026 | 36.73M |
| October 14, 2026 | 35.98M |
| Date | Value |
|---|---|
| October 13, 2026 | 31.18M |
| October 12, 2026 | 28.63M |
| October 09, 2026 | 29.08M |
| October 08, 2026 | 28.33M |
| October 07, 2026 | 26.98M |
| October 06, 2026 | 30.73M |
| October 05, 2026 | 29.98M |
| October 02, 2026 | 34.48M |
| October 01, 2026 | 36.28M |
| September 30, 2026 | 41.08M |
| September 29, 2026 | 115.14M |
| September 28, 2026 | 116.19M |
| September 25, 2026 | 114.54M |
| September 24, 2026 | 120.53M |
| September 23, 2026 | 119.49M |
| September 22, 2026 | 123.38M |
| September 21, 2026 | 114.24M |
| September 18, 2026 | 110.20M |
| September 17, 2026 | 108.25M |
| September 16, 2026 | 105.10M |
| September 15, 2026 | 100.01M |
| September 14, 2026 | 100.91M |
| September 11, 2026 | 96.26M |
| September 10, 2026 | 97.61M |
| September 09, 2026 | 94.76M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.774B |
| Corcept Therapeutics, Inc. | 7.301B |
| Veru, Inc. | 13.38M |
| Johnson & Johnson | 698.29B |
| Eli Lilly & Co. | 1.377T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.122M |
| Revenue (Quarterly) | 2.156M |
| Total Expenses (Quarterly) | 3.279M |
| EPS Diluted (Quarterly) | -0.19 |
| Gross Profit Margin (Quarterly) | 49.33% |
| Profit Margin (Quarterly) | -52.04% |
| Earnings Yield | -11.86% |
| Normalized Earnings Yield | -11.54 |